This marks the first targeted treatment for eosinophilic granulomatosis with polyangiitis (EGPA)
News
New NHS stroke treatment drug agreement could save 5,000 a year
This deal will see more patients having access to treatment which could prevent 21,700 strokes and 5,400 deaths
Pfizer signs deal to allow expanded use of COVID-19 treatment
Voluntary license agreement will allow generic versions of pill to be manufactured
EC approves Celltrion’s COVID-19 mAb Regkirona
Treatment authorised for use in adults with COVID-19 who are at high-risk of progressing to severe disease
Report: UK disposed of 600,000 AZ vaccine doses after they passed expiry date
The data was obtained by a Freedom of Information request, according to The Independent
NICE recommends cenobamate for treatment of adult epilepsy patients in UK
Epilepsy affects over 600,000 people in the UK, which is approximately one in every 100 people
JCVI advises extending COVID-19 booster programme
All adults aged 40- to 49-years-old to be offered an mRNA vaccine booster dose
Vertex receives CHMP positive opinion for Kaftrio in children with cystic fibrosis
Those eligible will have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene
NICE ‘no’ for BioMarin’s Vimizin
The draft guidance has been published following an evaluation of new evidence on the use of the treatment
New drug combination highly effective in children with leukaemia
APL is an acute leukaemia, meaning it develops quickly and requires immediate treatment
New COVID-19 vaccines could target replication proteins
Researchers have said that next generation vaccines for COVID-19 should aim to induce a response against ‘replication proteins’
New positive long-term data for JAK inhibitor Olumiant in RA
Olumiant maintained a consistent safety profile in a long-term analysis of patients with rheumatoid arthritis
Updated guidelines for managing long-term effects of COVID-19 published
New guidelines from NICE, SIGN and the RCGP includes an update to original list of common symptoms
Valneva receives EU deal for COVID jab, and seeks apology from UK
Decision follows the UK government’s termination of their deal with Valneva in September
University of Oxford begins human trials of Ebola vaccine
ChAdOxl biEBOV is being tested for safety and immunogenicity, and may protect against multiple species of the virus
